Background {#Sec1}
==========

Novel immunotherapeutic agents targeting CTLA-4, programmed cell death-1 protein receptor (PD-1), and the ligand PD-L1 are revolutionizing cancer therapy \[[@CR1]--[@CR7]\]. Cancer immunotherapy by re-igniting T cells through blocking PD-1 and PD-L1 is highly potent in a variety of malignancies \[[@CR8]--[@CR12]\]. Allogeneic hematopoietic stem cell transplantation has been proven to be a curative immunotherapy for leukemia though with significant toxicities \[[@CR13]--[@CR18]\]. Autologous T cells with re-engineered chimeric antigen receptors (CAR-T) have been successfully used for leukemia and lymphoma without graft-vs-host diseases \[[@CR19]--[@CR25]\]. The first such product, tisagenlecleucel, has recently been approved for clinical therapy of refractory B cell acute lymphoblastic lymphoma (ALL). More and more clinical trials of CAR-T cells are being done throughout the world \[[@CR26]--[@CR38]\].

In recent years, more and more clinical trials from China are being done and registered in [ClinicalTrials.gov](http://clinicaltrials.gov). CAR-T cells have become a major source of cellular immunotherapy in China. This study summarized the CAR-T clinical trials being conducted in China and provided a quick glimpse of the landscape of CAR-T studies in China.

Methods {#Sec2}
=======

We searched [ClinicalTrials.gov](http://clinicaltrials.gov) using keywords "CAR T," "CAR-T," "chimeric antigen receptor," "adoptive therapy," "third generation chimeric," and "fourth generation chimeric"; country: China. All relevant trials registered at the [ClinicalTrials.gov](http://clinicaltrials.gov) prior to July 18, 2017, were included in the analysis. One trial was excluded (NCT03121625) because the target antigen was not disclosed. A search of the PubMed database was also done to include those trials and cases that have been published.

Results {#Sec3}
=======

Distribution of CAR-T trials in China {#Sec4}
-------------------------------------

Currently, there are 121 trials reported and/or registered at [ClinicalTrials.gov](http://clinicaltrials.gov) from China (Table [1](#Tab1){ref-type="table"}). The trials are mainly carried out in leading hospitals from Beijing, Shanghai, Guangzhou, and Chongqing. CAR-T trials are started in hospitals throughout China. In this study, to avoid duplication of trials that can lead to miscalculation, those trials in Chinese registries were not included. It is possible that the number of institutions carrying out CAR-T trials will increase at a slower pace once regulatory policies are in place. We believe these CAR-T cells should be regulated as drugs \[[@CR39]\].Table 1Distribution of clinical trials with CAR-T cells in ChinaBeijing30Shanghai22Guangdong20Chongqing15Jiangsu13Others21

Chimeric antigen receptors, vectors, and co-stimulatory molecules used in the CAR constructs {#Sec5}
--------------------------------------------------------------------------------------------

T cell receptors (TCRs) are engineered by incorporating a specific antigen-targeting element and CD3 element to form a completely novel TCR structure, the chimeric antigen receptor (CAR) \[[@CR35], [@CR40]\]. In addition, several co-stimulating sequences have been used to facilitate the expansion of the CAR-T cells \[[@CR41]\]. CAR-engineered T lymphocytes have been in active clinical development to treat patients with advanced leukemia, lymphoma, and solid tumors \[[@CR42]--[@CR45]\].

One of the major hurdles in CAR-targeted cellular therapy has been the limited cell dose due to the lack of adequate in vivo cell expansion. Co-stimulatory signals can enhance immune responses of effector T cells \[[@CR46]\]. Inducible co-stimulatory signal (ICOS), 4-1BB (CD137), CD28, OX40 (CD134), CD27, and DAP10, along with CD3ζ, have been investigated \[[@CR31], [@CR47]--[@CR50]\]. Among these, 4-1BB (CD137), CD28, and CD3ζ are the most commonly used COS elements in the CARs (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}) \[[@CR51], [@CR52]\].Table 2Clinical trials of CD19-directed CAR-T cells in ChinaTarget antigenDiseasesCARVectorNCT no.CD19Leukemia, lymphoma4-1BB- CD3ζRVNCT01864889CD19B cell malignanciesCD28, CD137, CD27LVNCT03050190CD19MCL4-1BB-CD3ζRVNCT02081937CD19LeukemiaNANANCT03142646CD19B cell lymphomasCD27-CD3ζLVNCT02247609CD19Leukemia, lymphomaNANANCT02349698CD19Elderly relapsed/refractory B cell ALLNANANCT02799550CD19Leukemia, lymphomaNANANCT02537977CD19B cell leukemiaNANANCT02644655CD19B cell leukemia and lymphomaNANANCT02813837CD19B cell lymphomaNANANCT02547948CD19B cell lymphomaCD28-CD3ζRVNCT02652910CD19Leukemia, lymphomaCD28, CD3ζLV or RVNCT02456350CD19Recurrent or refractory acute non-T-lymphocyte leukemiaNANANCT02735291CD19LymphomaNANANCT02728882CD19Leukemia, lymphomaNANANCT02546739CD19B cell lymphomasNANANCT02842138CD19ALLNANANCT02810223CD19ALLCD28-CD137-CD3ζLVNCT02186860CD19B cell leukemia, B cell lymphomaCD3ζ, CD28, and 4-1BBLVNCT02963038CD19NHLTCRζ, 4-1BBLVNCT03029338CD19B cell ALLTCRζ, 4-1BBLVNCT02975687CD19B cell leukemia and lymphomaNALVNCT02933775CD19B cell leukemia4-1BBLVNCT02672501CD19Central nervous system B cell acute lymphocytic leukemiaNANANCT03064269CD19ALL4-1BBLVNCT02965092CD19Acute leukemiaNANANCT02822326CD19Leukemia, lymphomaCD28 or 4-1BB and a CD3ζLV or RVNCT03076437CD19Leukemia and lymphomaNANANCT02851589CD19Leukemia and lymphomaNANANCT02819583CD19DLBCLNALVNCT02976857CD19Recurrent or refractory B cell malignancyNANANCT02782351CD19Leukemia and lymphomaTCRz-CD28, TCRz-CD137NANCT02685670CD19B cell lymphoma4-1BB, CD3ζNANCT03101709CD19ALLNANANCT02924753CD19ALLNANANCT03027739CD19B cell leukemiaNALVNCT02968472CD19B cell lymphomaCD28ζNANCT02992834CD19AMLNANANCT03018093CD19Systemic lupus erythematosus4-1BBLVNCT03030976CD19NHLNALVNCT03154775CD19LymphomaNANANCT03086954CD19ALL, CLL, lymphomaCD28 or 4-1BB and CD3ζNANCT03191773CD19B cell lymphoma4-1BB-CD28-CD3NANCT03146533CD19LeukemiaNANANCT03173417CD19Relapsed or refractory B cell lymphoma4-1BBLVNCT03208556CD19B cell leukemia and lymphomaNCT03166878CD19B cell lymphomaNANANCT03118180CD19 or CD20Relapse/refractory B cell malignanciesNALVNCT02846584CD19 and CD20DLBCLNANANCT02737085CD19 and CD22Hematopoietic/lymphoid cancerTCRζ, 4-1BBNANCT02903810CD19/CD20B cell leukemia and lymphomaCD3ζ, 4-1BB-CD3ζRVNCT03097770CD19/CD22B cell malignancyNARVNCT03185494CD19/CD22B cell leukemia, B cell lymphomaNALVNCT03098355CD19/CD20/CD22/CD30B-NHLNANANCT03196830CD19/CD20B cell malignancyNANANCT03207178CD19 and CD20/CD22/CD38/CD123B cell malignancyNALVNCT03125577*AMMS* Academy Military Medical Sciences, *ALL* acute lymphoblastic leukemia, *AML* acute myeloid leukemia, *BCMA* B cell maturation antigen, *CTX* cyclophosphamide, *DLBCL* diffuse large B cell lymphoma, *FLU* fludarabine, *HL* Hodgkin's lymphoma, *LV* lentiviral, *MCL* mantle cell lymphoma, *N*A not available, *NHL* non-Hodgkin lymphoma, *RV* retroviral, *TCM* traditional Chinese medicine Table 3Clinical trials of CAR-T cells targeting non-CD19 antigens in ChinaTarget AntigenDiseaseCARVectorNCT no.CD20Lymphoma4-1BB-CD3ζLVNCT01735604CD20B cell lymphomaCD3ζ and CD28RVNCT02965157CD20B cell malignanciesNANANCT02710149CD22CD19-refractory or resistant lymphomaTCRζ, 4-1BBRVNCT02721407CD22Recurrent or refractory B cell malignancyNANANCT02794961CD22B cell malignanciesNANANCT02935153CD30LymphomaNALVNCT02274584CD30HL, NHLNANANCT02259556CD30Lymphocyte malignanciesNANANCT02958410CD33AML4-1BB-CD3ζRVNCT01864902CD33AMLNANANCT02799680CD33Myeloid malignanciesNANANCT02958397BCMAB cell malignanciesNANANCT02954445BCMAMultiple myelomaTCRζ, 4-1-BBRVNCT03093168CD123LeukemiaNANANCT02937103CD123AML recurred after allo-HSCT41BB-CD3ζNANCT03114670CD138Multiple myeloma4-1BB-CD3ζRVNCT01886976CD138/BCMAMultiple myelomaNANANCT03196414Lewis-YMyeloid malignanciesNANANCT02958384*AMMS* Academy of Military Medical Sciences, *ALL* acute lymphoblastic leukemia, *AML* acute myeloid leukemia, *BCMA* B cell maturation antigen, *CTX* cyclophosphamide, *FLU* fludarabine, *HL* Hodgkin's lymphoma, *LV* lentiviral, *MCL* mantle cell lymphoma, *NA* not available, *NHL* non-Hodgkin lymphoma, *RV* retroviral, *TCM* traditional Chinese medicine Table 4Clinical trials of CAR-T cells for solid tumors in ChinaTarget antigensDiseasesCARVectorNCT no.GPC3Hepatocellular carcinomaNANANCT02723942GPC3Hepatocellular carcinomaCD3ζ, CD28, and 4-1BBNANCT02395250GPC3Lung squamous cell carcinomaNALVNCT02876978GPC3Hepatocellular carcinoma and liver metastases4-1BBNANCT02715362GPC3Hepatocellular carcinoma4-1BBNANCT03130712GPC3Advanced hepatocellular carcinoma4-1BB-CD3ζRVNCT03084380GPC3Hepatocellular carcinoma, squamous cell lung cancerNANANCT03198546GPC3Hepatocellular carcinomaNALVNCT03146234GPC3, mesothelin, CEAHepatocellular, pancreatic cancer, colorectal cancerNALVNCT02959151MesothelinMalignant mesothelioma, pancreatic Cancer, ovarian tumor, triple-negative breast cancer, endometrial cancer, other mesothelin-positive tumors4-1BB-CD3ζRVNCT02580747MesothelinRecurrent or metastatic malignant tumorsNANANCT02930993MesothelinPancreatic cancer and pancreatic ductal a denocarcinoma4-1BBNANCT02706782MesothelinSolid tumor, adult advanced cancerNANANCT03030001MesothelinAdvanced solid tumorNANANCT03182803EpCAMLiver neoplasmsNANANCT02729493EpCAMStomach neoplasmsNANANCT02725125EpCAMNasopharyngeal carcinoma and breast cancerNALVNCT02915445EpCAMColon cancer, esophageal carcinoma, pancreatic cancer, prostate cancer, gastric cancer, hepatic carcinomaCD3ζ, CD28LVNCT03013712GD2NeuroblastomaNALVNCT02765243GD2Relapsed or refractory neuroblastomaNANANCT02919046GD2Solid tumorNALVNCT02992210HER-2Advanced HER-2-positive solid tumorsCD3ζ, 4-1BB-CD3ζNANCT01935843HER-2Breast cancerCD28-CD3ζRVNCT02547961HER-2Breast cancer, ovarian cancer, lung cancer, gastric cancer, glioma, pancreatic cancerNANANCT02713984EGFRAdvanced EGFR-positive solid tumors4-1BB-CD3ζLVNCT01869166EGFRAdvanced solid tumorNANANCT03182816EGFRColorectal cancer4-1BB-CD28-CD3NANCT03152435EGFRvIIIRecurrent glioblastoma multiformNALVNCT02844062EGFRvIIIGlioblastoma multiformNANANCT03170141MUC1Malignant glioma of brain, colorectal carcinoma, gastric carcinomaNANANCT02617134MUC1Advanced refractory solid tumor (hepatocellular carcinoma, NSCLC, pancreatic carcinoma, triple-negative invasive breast carcinoma)CD28-4-1BB- CD3ζLVNCT02587689MUC1Advanced solid tumorNANANCT03179007CEALung cancer, colorectal cancer, gastric cancer, breast cancer, pancreatic cancerNANANCT02349724EphA2EphA2-positive malignant gliomaNANANCT02575261LMP1Nasopharyngeal neoplasmsNANANCT02980315MG7Liver metastases4-1BBNANCT02862704CD133Liver cancer, pancreatic cancer, brain tumor, breast cancer, ovarian tumor, colorectal cancer, ALL, AMLCD3ζ, 4-1BB-CD3ζRVNCT02541370HerinCAR-PD1Advanced malignanciesNANANCT02873390HerinCAR-PD1Advanced solid tumor (lung, liver, and stomach)NANANCT02862028PD-L1 CSRGlioblastoma multiformNANANCT02937844NY-ESO-1Advanced NSCLCNALVNCT03029273ZeushieldNSCLCNANANCT03060343PSCA/MUC1/PD-L1/CD80/86Advanced lung or other cancersNANANCT03198052PSMA, FRaBladder cancer, urothelial carcinoma bladderNANANCT03185468Claudin18.2Advanced gastric adenocarcinoma, pancreatic adenocarcinomaNALVNCT03159819*CTX* cyclophosphamide, *FLU* fludarabine, *LV* lentiviral, *NA* not available, *NSCLC* non-small cell lung cancer, *RV* retroviral

Most CARs in the CAR-T trials in China are second-generation CAR constructs, which have one co-stimulatory signal \[[@CR41]\]. A trial of CAR-T cells containing a third-generation CAR construct with both CD28 and CD137 co-stimulatory signals is still recruiting patients with relapsed/refractory ALL (NCT02186860). Fourth-generation CARs have incorporated additional elements in the CAR constructs, such as an inducible caspase-9 gene element that can lead to self-destruction by apoptosis of the CAR-T cells \[[@CR53]\]. A total of 10 trials of CAR-T cells contain a fourth-generation CAR (Table [5](#Tab5){ref-type="table"}). Among these, five trials are evaluating CARs with an inducible caspase-9 suicide switch.Table 5Clinical trials of CAR-T cells with fourth-generation CARs in ChinaTarget antigenDiseaseVectorNCT no.CD19B cell malignanciesLVNCT03050190CD19B cell lymphomasLVNCT02247609CD19B cell leukemiaLVNCT02968472CD19/CD22B cell leukemia, B cell lymphomaLVNCT03098355CD19 and CD20/CD22/CD38/CD123B cell malignancyLVNCT03125577CD30LymphomaLVNCT02274584PSMA, FRaBladder cancer, urothelial carcinoma bladderNANCT03185468EGFRvIIIGlioblastoma multiformNANCT03170141GD2NeuroblastomaLVNCT02765243GD2Solid tumorLVNCT02992210*LV* lentiviral vector, *NA* not available

The recombinant CAR cassette is typically packaged into a pseudo-lentivirus vector which can efficiently incorporate into the genome of T cells. To date, the lentiviral vector is the most commonly used vector in CAR-T cells. The other vector commonly used is the retroviral vector (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}).

Antigen targets {#Sec6}
---------------

By altering a specific antigen-targeting element, the specificity of the CAR-T cells can be easily re-directed to a specific type of malignancy. This makes the CAR-T cell therapy highly versatile. A number of antigens have been targeted in this way. More and more antigens are being engineered into CAR-T cells, leading to a large repertoire of CAR-T cells that are being explored for the therapy of both solid and hematological malignancies (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).

CD19 is the most commonly targeted antigen to date (Table [2](#Tab2){ref-type="table"}). Out of the 121 trials, 57 trials have CD19 as a target. Currently, there are 19 clinical trials in China targeting non-CD19 antigens, including CD20, CD22, CD30, CD33, CD38, CD123, CD138, BCMA, and Lewis Y antigen for hematological malignancies (Table [3](#Tab3){ref-type="table"}). Dual- and multi-specificity CAR-T cells have also been in clinical trials in China.

Current trials on hematological malignancies {#Sec7}
--------------------------------------------

The most common type of diseases in CAR-T trials are B cell malignancies, including leukemia, lymphoma, and myeloma.

The CD19-targeted autologous CAR-T product, tisagenlecleucel, was recently approved by FDA for therapy of refractory/relapsed (r/r) B cell ALL. In 30 patients including children and adults who received this product, 90% of them achieved complete remission (CR) \[[@CR54]\]. Severe cytokine-release syndrome (CRS) was reported in 27% of the patients. This product has been in clinical trials for CD19+ B cell malignancies, including CLL, ALL, and lymphoma \[[@CR21]--[@CR24], [@CR54], [@CR55]\]. In a Chinese study (NCT 02813837), 30 patients (5 children and 25 adults) with r/r ALL were treated with autologous CD-19 CAR-T cells \[[@CR56]\]. In this 2017 report of preliminary results of a seven-center clinical trial, CR was 86% and severe CRS was seen in 26% of the patients \[[@CR56]\]. Successful outcome has been reported with other CAR-T cells against CD19 antigen in r/r ALL \[[@CR29], [@CR32], [@CR57]--[@CR59]\].

The CD19-specific CAR-T cells, axicabtagene ciloleucel (axi-cel, KTE-C19), have been reported to be safe for treatment of aggressive lymphomas including r/r diffuse large cell lymphoma (DLBCL) \[[@CR25]\]. In the phase II part of the ZUMA-1 trial, overall response rate (ORR) was 76% (47% CR and 29% PR) at the time of report in the cohort 1 of 51 patients \[[@CR60]\]. This product is currently under evaluation by FDA.

CD33 and CD123 are targets on myeloid leukemias. Currently, there are three trials on CAR-T cells targeting CD33 and two trials targeting CD123 antigen in China (Table [3](#Tab3){ref-type="table"}). In the USA, three CAR-T trials targeting CD123 were either terminated (NCT02623582) or suspended (UCART123, NCT02159495, and NCT03190278) at this time.

B cell maturation antigen (BCMA) is an antigen target on myeloma cells. Currently, three trials on BCMA-targeted CAR-T cells are being done in r/r myeloma in China (Table [3](#Tab3){ref-type="table"}). In one of the trials of CAR-T cells targeting BCMA in China, 19 patients with r/r multiple myeloma were evaluable and 7 of the patients were followed for more than 6 months at the time of the report \[[@CR61]\]. CRS was observed in 14 (74%) patients. The ORRs were close to 100% in the evaluable r/r myeloma patients. The outcome from the preliminary report was highly encouraging. Complete response was also reported in a case of r/r myeloma patient who received autologous CTL019 cells, even though 99.95% of the myeloma cells were negative for CD19 \[[@CR38], [@CR62]\]. It appears therefore that multiple myeloma is highly sensitive to immunotherapy.

There are also a few registered clinical trials that are testing two or more CARs either simultaneously or sequentially. In the trial NCT02846584, patients receive intravenously infused autologous anti-CD19 or anti-CD20 CAR-T cells to treat B cell malignancies. Another trial, NCT02737085, is to explore the sequential therapeutic effect of anti-CD19 and anti-CD20 CAR-T cells in the treatment of DLBCL.

The trial NCT02903810 was planned with a treatment scheme of infusion of equal numbers of anti-CD19 and anti-CD22 CAR-T cells in the treatment of refractory hematologic malignancies. Two trials (NCT03097770 and NCT03098355) target two antigens simultaneously with one CAR construct (Table [2](#Tab2){ref-type="table"}). These trials are ongoing at this time.

Current trials on solid tumors {#Sec8}
------------------------------

Multiple solid tumors are being studied in CAR-T clinical trials. At the time of this report, 20 different antigens are being targeted in solid tumor trials (Table [4](#Tab4){ref-type="table"}). GPC3, mesothelin, epidermal growth factor receptor (EGFR), and EpCAM were the most targeted antigens (Table [4](#Tab4){ref-type="table"}). This is consistent with reports from international trials \[[@CR63]--[@CR68]\]. Liver cancer remains the most commonly studied solid tumor in China \[[@CR69]\]. In a preliminary report of a trial of CAR-T cells against CD133+ epithelial tumors (NCT02541370), 24 patients were enrolled, including 14 patients with sorafenib-refractory hepatocellular carcinoma (HCC), 7 with pancreatic carcinomas, 2 with colorectal carcinomas, and 1 with cholangiocarcinoma \[[@CR69]\]. The number of CAR-T cells was found to be inversely related to the CD133+ epithelial cells in peripheral blood. There was a separate report treating refractory cholangiocarcinoma with sequential infusion of two different types of CAR-T cells targeting EGFR and CD133 \[[@CR70]\].

Two trials in China are evaluating GD2 antigen-targeted CAR-T cells in neuroblastoma (Table [4](#Tab4){ref-type="table"}). Another two trials are evaluating CAR-T cells against EGFRvIII+ glioblastoma. There was one case report in the literature on rapidly progressing refractory glioblastoma that showed dramatic CR to IL13Rα2-targeted CAR-T cells after repeated infusion \[[@CR71]\]. In a separate report, nine patients with refractory EGFRvIII+ glioblastoma received autologous CART-EGFRvIII cells in a pilot study \[[@CR66]\]. Interestingly, there was no CRS observed. CAR-T cell infiltration was shown in the resected tumor specimen. This study suggested that the CAR-T cells are safe and immunologically active with tracking capability to the cancer cells in the brain.

Multiple antigens are being explored as targets in solid tumors for CAR-T cells (Table [4](#Tab4){ref-type="table"}). Preliminary reports have been presented and published throughout the world \[[@CR64], [@CR65], [@CR67], [@CR72]\]. Outcomes from larger sample size and longer follow-up are clearly needed from these trials.

CAR-T trials for non-malignant diseases {#Sec9}
---------------------------------------

There is currently one clinical trial of autologous CAR-T19 cells for patients with systemic lupus erythematosus (NCT03030976, Table [2](#Tab2){ref-type="table"}). This trial is designed to infuse 1 × 10^6^ cells/kg. More trials are expected to come for non-malignant diseases.

Discussion {#Sec10}
==========

This study analyzed CAR-T trials in China. Most CAR-T trials are employing autologous T cells. CD19 is the most commonly targeted antigen. Therefore, B cell leukemia and lymphoma are the most common malignancies in CAR-T trials. Solid tumors remain a significant challenge for CAR-T therapy \[[@CR45], [@CR70], [@CR73], [@CR74]\]. Challenges include selection of target antigens, management of toxicities, and modulation of tumor microenvironment \[[@CR75], [@CR76]\]. Loss of CD19 expression is a known mechanism for relapse from CD19-directed CAR-T therapy \[[@CR77]\]. The first CAR-T product, tisagenlecleucel, was recently approved. KTE-C19 for large cell lymphoma is under evaluation by FDA \[[@CR25], [@CR60]\]. It is unclear which product among many ongoing clinical CAR-T trials in China has independent patent that may lead to final approval for clinical application in China.

It has been well documented that CAR-T cells can cross the blood-brain barrier \[[@CR23], [@CR78], [@CR79]\]. CAR-T cells may become an effective therapy for refractory CNS diseases \[[@CR66], [@CR71], [@CR78]--[@CR81]\]. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications \[[@CR70]\]. Multi-target CAR-engineered T cells are also entering clinical trials (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}).

The currently approved tisagenlecleucel CAR-T therapy relies on transduction of autologous T cells from patients. It is important therefore to be able to reliably obtain and propagate adequate amount of T cells. This may become a major limitation for wide application of this new therapy. Therefore, newer CARs are being actively investigated \[[@CR41], [@CR82]--[@CR84]\]. Universal CAR-Ts have been generated by inactivating HLA class I molecules and used successfully in patients \[[@CR82], [@CR85], [@CR86]\]. Allogeneic CAR-T cells are entering clinical trials \[[@CR42], [@CR87]\]. T cell receptor-engineered CAR-T cells represent another frontier in CAR-T cell development \[[@CR88]--[@CR90]\]. It is foreseeable that CAR-T immunotherapy will become a major modality of cancer therapy (Table [5](#Tab5){ref-type="table"}) \[[@CR91]\].
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